HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Pacira BioSciences (NASDAQ:PCRX) but lowered the price target from $57 to $39.
August 12, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Pacira BioSciences but lowered the price target from $57 to $39.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100